Exploring the neuroregenerative potential of tacrolimus

T. M. Saffari, M. Bedar, J. M. Zuidam, A. Y. Shin, C. C. Baan, D. A. Hesselink, C. A. Hundepool

Research output: Contribution to journalReview article

Abstract

Introduction: The clinical use of tacrolimus is characterized by many side effects which include neurotoxicity. In contrast, tacrolimus has also shown to have neuroregenerative properties. On a molecular level, the mechanisms of action could provide us more insight into understanding the neurobiological effects. The aim of this article is to review current evidence regarding the use of tacrolimus in peripheral nerve injuries. Areas covered: Available data on tacrolimus’ indications were summarized and molecular mechanisms were elucidated to possibly understand the conflicting neurotoxic and neuroregenerative effects. The potential clinical applications of tacrolimus, as immunosuppressant and enhancer of nerve regeneration in peripheral nerve injuries, are discussed. Finally, concepts of delivery are explored. Expert opinion: It is unclear what the exact neurobiological effects of tacrolimus are. Besides its known calcineurin inhibiting properties, the mechanism of action of tacrolimus is mediated by its binding to FK506-binding protein-52, resulting in a bimodal dose response. Experimental models found that tacrolimus administration is preferred up to three days prior to or within 10 days post-nerve reconstruction. Moreover, the indication for the use of tacrolimus has been expanding to fields of dermatology, ophthalmology, orthopedic surgery and rheumatology to improve outcomes after various indications.

Original languageEnglish (US)
Pages (from-to)1047-1057
Number of pages11
JournalExpert Review of Clinical Pharmacology
Volume12
Issue number11
DOIs
StatePublished - Nov 2 2019

Fingerprint

Tacrolimus
Peripheral Nerve Injuries
Tacrolimus Binding Proteins
Nerve Regeneration
Calcineurin
Expert Testimony
Rheumatology
Ophthalmology
Immunosuppressive Agents
Dermatology
Orthopedics
Theoretical Models

Keywords

  • allograft rejection
  • Calcineurin inhibitor
  • nerve injury
  • neuroregeneration
  • neurotoxicity
  • tacrolimus
  • transplantation

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Saffari, T. M., Bedar, M., Zuidam, J. M., Shin, A. Y., Baan, C. C., Hesselink, D. A., & Hundepool, C. A. (2019). Exploring the neuroregenerative potential of tacrolimus. Expert Review of Clinical Pharmacology, 12(11), 1047-1057. https://doi.org/10.1080/17512433.2019.1675507

Exploring the neuroregenerative potential of tacrolimus. / Saffari, T. M.; Bedar, M.; Zuidam, J. M.; Shin, A. Y.; Baan, C. C.; Hesselink, D. A.; Hundepool, C. A.

In: Expert Review of Clinical Pharmacology, Vol. 12, No. 11, 02.11.2019, p. 1047-1057.

Research output: Contribution to journalReview article

Saffari, TM, Bedar, M, Zuidam, JM, Shin, AY, Baan, CC, Hesselink, DA & Hundepool, CA 2019, 'Exploring the neuroregenerative potential of tacrolimus', Expert Review of Clinical Pharmacology, vol. 12, no. 11, pp. 1047-1057. https://doi.org/10.1080/17512433.2019.1675507
Saffari, T. M. ; Bedar, M. ; Zuidam, J. M. ; Shin, A. Y. ; Baan, C. C. ; Hesselink, D. A. ; Hundepool, C. A. / Exploring the neuroregenerative potential of tacrolimus. In: Expert Review of Clinical Pharmacology. 2019 ; Vol. 12, No. 11. pp. 1047-1057.
@article{4fa46ead6a314b35abac968ac4c8d457,
title = "Exploring the neuroregenerative potential of tacrolimus",
abstract = "Introduction: The clinical use of tacrolimus is characterized by many side effects which include neurotoxicity. In contrast, tacrolimus has also shown to have neuroregenerative properties. On a molecular level, the mechanisms of action could provide us more insight into understanding the neurobiological effects. The aim of this article is to review current evidence regarding the use of tacrolimus in peripheral nerve injuries. Areas covered: Available data on tacrolimus’ indications were summarized and molecular mechanisms were elucidated to possibly understand the conflicting neurotoxic and neuroregenerative effects. The potential clinical applications of tacrolimus, as immunosuppressant and enhancer of nerve regeneration in peripheral nerve injuries, are discussed. Finally, concepts of delivery are explored. Expert opinion: It is unclear what the exact neurobiological effects of tacrolimus are. Besides its known calcineurin inhibiting properties, the mechanism of action of tacrolimus is mediated by its binding to FK506-binding protein-52, resulting in a bimodal dose response. Experimental models found that tacrolimus administration is preferred up to three days prior to or within 10 days post-nerve reconstruction. Moreover, the indication for the use of tacrolimus has been expanding to fields of dermatology, ophthalmology, orthopedic surgery and rheumatology to improve outcomes after various indications.",
keywords = "allograft rejection, Calcineurin inhibitor, nerve injury, neuroregeneration, neurotoxicity, tacrolimus, transplantation",
author = "Saffari, {T. M.} and M. Bedar and Zuidam, {J. M.} and Shin, {A. Y.} and Baan, {C. C.} and Hesselink, {D. A.} and Hundepool, {C. A.}",
year = "2019",
month = "11",
day = "2",
doi = "10.1080/17512433.2019.1675507",
language = "English (US)",
volume = "12",
pages = "1047--1057",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Exploring the neuroregenerative potential of tacrolimus

AU - Saffari, T. M.

AU - Bedar, M.

AU - Zuidam, J. M.

AU - Shin, A. Y.

AU - Baan, C. C.

AU - Hesselink, D. A.

AU - Hundepool, C. A.

PY - 2019/11/2

Y1 - 2019/11/2

N2 - Introduction: The clinical use of tacrolimus is characterized by many side effects which include neurotoxicity. In contrast, tacrolimus has also shown to have neuroregenerative properties. On a molecular level, the mechanisms of action could provide us more insight into understanding the neurobiological effects. The aim of this article is to review current evidence regarding the use of tacrolimus in peripheral nerve injuries. Areas covered: Available data on tacrolimus’ indications were summarized and molecular mechanisms were elucidated to possibly understand the conflicting neurotoxic and neuroregenerative effects. The potential clinical applications of tacrolimus, as immunosuppressant and enhancer of nerve regeneration in peripheral nerve injuries, are discussed. Finally, concepts of delivery are explored. Expert opinion: It is unclear what the exact neurobiological effects of tacrolimus are. Besides its known calcineurin inhibiting properties, the mechanism of action of tacrolimus is mediated by its binding to FK506-binding protein-52, resulting in a bimodal dose response. Experimental models found that tacrolimus administration is preferred up to three days prior to or within 10 days post-nerve reconstruction. Moreover, the indication for the use of tacrolimus has been expanding to fields of dermatology, ophthalmology, orthopedic surgery and rheumatology to improve outcomes after various indications.

AB - Introduction: The clinical use of tacrolimus is characterized by many side effects which include neurotoxicity. In contrast, tacrolimus has also shown to have neuroregenerative properties. On a molecular level, the mechanisms of action could provide us more insight into understanding the neurobiological effects. The aim of this article is to review current evidence regarding the use of tacrolimus in peripheral nerve injuries. Areas covered: Available data on tacrolimus’ indications were summarized and molecular mechanisms were elucidated to possibly understand the conflicting neurotoxic and neuroregenerative effects. The potential clinical applications of tacrolimus, as immunosuppressant and enhancer of nerve regeneration in peripheral nerve injuries, are discussed. Finally, concepts of delivery are explored. Expert opinion: It is unclear what the exact neurobiological effects of tacrolimus are. Besides its known calcineurin inhibiting properties, the mechanism of action of tacrolimus is mediated by its binding to FK506-binding protein-52, resulting in a bimodal dose response. Experimental models found that tacrolimus administration is preferred up to three days prior to or within 10 days post-nerve reconstruction. Moreover, the indication for the use of tacrolimus has been expanding to fields of dermatology, ophthalmology, orthopedic surgery and rheumatology to improve outcomes after various indications.

KW - allograft rejection

KW - Calcineurin inhibitor

KW - nerve injury

KW - neuroregeneration

KW - neurotoxicity

KW - tacrolimus

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=85074264056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074264056&partnerID=8YFLogxK

U2 - 10.1080/17512433.2019.1675507

DO - 10.1080/17512433.2019.1675507

M3 - Review article

C2 - 31575290

AN - SCOPUS:85074264056

VL - 12

SP - 1047

EP - 1057

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 11

ER -